You are here

CDC Updates Guidelines on Sexually Transmitted Disease

Agency notes that treatment is complicated by antimicrobial resistance

The agency’s revised guidelines were published in the August 10 issue of Morbidity and Mortality Weekly Report.

For the treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea, the CDC now recommends combination therapy with a single intramuscular dose of ceftriaxone 250 mg plus either a single dose of azithromycin 1 g orally or doxycycline 100 mg orally twice daily for 7 days.

When ceftriaxone cannot be used for the treatment of urogenital or rectal gonorrhea, two alternative options are available: 1) cefixime 400 mg orally plus either azithromycin 1 g orally or doxycycline 100 mg twice daily orally for 7 days if ceftriaxone is not readily available, or 2) azithromycin 2 g orally in a single dose if ceftriaxone cannot be given because of severe allergy.

Gonorrhea is a major cause of serious reproductive complications in women and can facilitate the transmission of human immunodeficiency virus (HIV). Effective treatment is a cornerstone of U.S. gonorrhea control efforts, the CDC says, but treatment of the disease has been complicated by the ability of Neisseria gonorrhoeae to develop antimicrobial resistance.

For more information, visit the CDC Web site.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile